Cargando…

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer

The androgen receptor (AR) is the main therapeutic target in advanced prostate cancer, because it regulates the growth and progression of prostate cancer cells. Patients may undergo multiple lines of AR-directed treatments, including androgen-deprivation therapy, AR signaling inhibitors (abiraterone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obinata, Daisuke, Lawrence, Mitchell G., Takayama, Kenichi, Choo, Nicholas, Risbridger, Gail P., Takahashi, Satoru, Inoue, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578370/ https://www.ncbi.nlm.nih.gov/pubmed/33134178 http://dx.doi.org/10.3389/fonc.2020.581515

Ejemplares similares

Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2017)

OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer
por: Obinata, Daisuke, et al.
Publicado: (2022)

CLDN8, an androgen‐regulated gene, promotes prostate cancer cell proliferation and migration
por: Ashikari, Daisaku, et al.
Publicado: (2017)

Identification of new octamer transcription factor 1‐target genes upregulated in castration‐resistant prostate cancer
por: Yamamoto, Shinichiro, et al.
Publicado: (2019)

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
por: Obinata, Daisuke, et al.
Publicado: (2023)

Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
por: Fujimura, Tetsuya, et al.
Publicado: (2018)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells
por: Migita, Toshiro, et al.
Publicado: (2017)

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

Ceramide Regulates Anti-Tumor Mechanisms of Erianin in Androgen-Sensitive and Castration-Resistant Prostate Cancers
por: Trapika, I Gusti Md Gde Surya C., et al.
Publicado: (2021)

The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression
por: Gao, Lin, et al.
Publicado: (2022)

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
por: Di Nunno, Vincenzo, et al.
Publicado: (2018)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
por: Kattan, Michael W., et al.
Publicado: (2020)

An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy
por: Yoshizawa, Tsuyoshi, et al.
Publicado: (2019)

Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis
por: Mulati, Yelin, et al.
Publicado: (2021)

SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease
por: Risbridger, Gail, et al.
Publicado: (2019)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis
por: Zhao, Shankun, et al.
Publicado: (2023)

PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery
por: Risbridger, Gail P, et al.
Publicado: (2020)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jiaxin, et al.
Publicado: (2020)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Androgen‐responsive tripartite motif 36 enhances tumor‐suppressive effect by regulating apoptosis‐related pathway in prostate cancer
por: Kimura, Naoki, et al.
Publicado: (2018)

Clinical Significance of Amyloid Precursor Protein in Patients with Testicular Germ Cell Tumor
por: Yamada, Yuta, et al.
Publicado: (2013)

Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression
por: Takayama, Ken-ichi, et al.
Publicado: (2017)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
por: Kobayashi, Takashi, et al.
Publicado: (2013)

Pro‐tumorigenic role of ERα in prostate cancer cells
por: Furic, Luc, et al.
Publicado: (2015)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022)

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
por: Wang, Zhize, et al.
Publicado: (2020)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer
por: Takayama, Ken-ichi, et al.
Publicado: (2014)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
por: Lam, Hung-Ming, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_op7b10gkblor6bvlq2r12ssdao